Connect with us

Technology

Invest Smart, Grow Fast! Industries with Up to 20% Annual Growth

Published

on

“Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns”

BOSTON, Oct. 30, 2024 /PRNewswire/ — CAGR offers a clear view of long-term investment trends by balancing fluctuations for a steady growth rate. BCC Research reveals exciting growth opportunities, with specific industries poised for notable expansion—ideal for investors and stakeholders looking ahead.

1.  Zero Net Energy Buildings: Global Markets The global market for Zero Net Energy Buildings (ZNEBs) – which produce as much energy as they consume – is experiencing rapid growth. In 2022, the market size was $42.8 billion, but it’s expected to more than double to $109.2 billion by 2027. This represents an impressive annual growth rate of 20.6% over the next five years. As concern for climate change and energy efficiency continues to rise, the demand for ZNEBs is surging, driving innovation and investment in this sustainable and forward-thinking industry.

Microsoft: Microsoft’s Silicon Valley campus features a ZNEB design, with a focus on energy efficiency, renewable energy, and sustainable materials. The campus includes features like solar panels, green roofs, and advanced energy management systems to minimize energy consumption.Walgreens: Walgreens’ net-zero energy store in Evanston, Illinois, is a prime example of ZNEB in retail. The store features solar panels, wind turbines, and geothermal energy systems to power its operations. The building is designed to produce as much energy as it consumes over the course of a year.

2.  RNAi Drug Delivery: Technologies and Global Markets  The market for delivering RNA interference (RNAi) drugs, which use genetic material to treat diseases, is growing rapidly. Currently valued at $1.1 billion, it’s expected to nearly triple to $2.7 billion by 2028, with a remarkable annual growth rate of 20.5%. This surge is driven by advancements in technologies that help get these drugs into the body effectively, opening new possibilities for treating a range of medical conditions. As research and development continue to improve, the potential for RNAi drugs to revolutionize healthcare is vast, making this an exciting and promising field.

Alnylam Pharmaceuticals: Alnylam is a leading developer of RNAi therapeutics, with several approved treatments for rare genetic diseases. Their technology uses lipid nanoparticles to deliver RNAi drugs to specific cells, silencing disease-causing genes.Arrowhead Pharmaceuticals: Arrowhead is another prominent player in RNAi drug delivery, with a focus on developing treatments for liver and cardiovascular diseases. Their proprietary Targeted RNAi Molecule (TRiM) technology enables precise delivery of RNAi drugs to specific cells, reducing off-target effects.

3.  Biologics Development and Manufacturing Testing: Technologies and Global Markets The market for testing the safety of biologics, which are complex medicines made from living cells, is growing rapidly. Currently valued at $7.4 billion, it’s expected to more than double to $18.2 billion by 2027, with an impressive annual growth rate of 19.9%. This surge is driven by the increasing demand for biologics to treat various diseases, and the need for rigorous testing to ensure their safety and effectiveness. As biologics become more prevalent in healthcare, the importance of thorough testing and quality control grows, making this a critical and expanding field.

Pfizer: Pfizer, a global pharmaceutical giant, uses advanced biologics safety testing technologies to ensure the quality and efficacy of its biologic medicines. Their testing protocols include state-of-the-art analytical techniques, such as mass spectrometry and chromatography, to detect impurities and ensure product consistency.Biogen: Biogen, a leading biotechnology company, employs rigorous biologics safety testing methods to develop and manufacture innovative treatments for complex diseases. Their testing strategies include cutting-edge technologies like next-generation sequencing and advanced bioinformatics to identify potential safety risks and optimize product development.

4.  Viral Vector and Plasmid DNA: Technologies and Global Markets The market for viral vector and plasmid DNA technologies, which are crucial tools for developing gene therapies and vaccines, is experiencing rapid growth. Currently valued at $2.9 billion, it’s expected to more than double to $7.1 billion by 2028, with an impressive annual growth rate of 19.7%. This surge is driven by the increasing demand for innovative treatments for genetic diseases and infectious diseases, as well as advancements in technologies that enable precise gene editing and delivery. As researchers and companies continue to harness the power of genetic medicine, the demand for these technologies is skyrocketing, making this a dynamic and promising field.

Moderna Therapeutics: Moderna, a pioneering biotech company, uses viral vector technology to develop innovative mRNA-based vaccines and therapies. Their platform leverages a type of viral vector called lipid nanoparticles to deliver genetic material to cells, instructing them to produce specific proteins.Spark Therapeutics: Spark Therapeutics, a leading gene therapy company, utilizes viral vectors to develop treatments for inherited diseases. Their technology employs adeno-associated virus (AAV) vectors to deliver healthy copies of a gene to cells, replacing faulty or missing genes that cause disease.

5.  Inkjet Printing Technologies: Applications and Asia-Pacific Markets The market for inkjet printing technologies in the Asia-Pacific region is booming! Currently valued at $7.4 billion, it’s expected to more than double to $18.2 billion by 2028, growing at an impressive rate of 19.6% each year. This surge is driven by increasing demand for high-quality printing in various industries, such as textiles, ceramics, and packaging. Advancements in inkjet technology have made it faster, more precise, and cost-effective, making it an attractive option for businesses looking to enhance their printing capabilities. As a result, the Asia-Pacific market is poised for significant growth, with new opportunities emerging for companies that adopt this innovative technology.

Epson: Epson, a renowned electronics company, utilizes inkjet printing technology in its wide-format printers for various applications, including signage, textiles, and ceramics. Their proprietary Micro Piezo printheads enable precise droplet control, resulting in high-quality prints.Canon: Canon, a leading imaging and optical products company, employs inkjet printing technology in its production printers for high-speed, high-quality printing. Their inkjet technology is used in various industries, including commercial printing, packaging, and labels, offering efficient and reliable printing solutions.

6.  Global Electrical Vehicle Battery Market The market for electric vehicle (EV) batteries is rapidly accelerating! Was valued at $66.4 billion, it’s expected to nearly triple to $161.3 billion by 2028, growing at an impressive rate of 19.4% each year. This surge is driven by the increasing adoption of electric vehicles, government initiatives promoting sustainable transportation, and advancements in battery technology. As EVs become more mainstream, the demand for high-performance, efficient, and cost-effective batteries is skyrocketing, making this market a hotbed of innovation and growth. With major players investing heavily in research and development, the future of EV batteries looks bright and electrifying!

Tesla: Tesla, a pioneering electric vehicle manufacturer, designs and produces its own EV batteries, including the popular Lithium-Ion battery cells. Their battery technology powers their entire range of electric vehicles, including the Model S, Model 3, and Model Y.LG Chem: LG Chem, a leading chemical and battery manufacturer, supplies EV batteries to several major automotive companies, including General Motors, Ford, and Hyundai. Their advanced battery technology, including Lithium-Ion and Nickel-Manganese-Cobalt (NMC) batteries, enables efficient and reliable EV performance.

7.  Next-generation Sequencing: Emerging Clinical Applications and Global Markets The market for next-generation sequencing (NGS) in clinical settings is experiencing rapid growth! Currently valued at $21.9 billion, it’s expected to more than double to $52.9 billion by 2028, with an impressive annual growth rate of 19.3%. This surge is driven by the increasing adoption of NGS in healthcare, enabling precise diagnosis, personalized treatment, and targeted therapies. NGS technology allows for rapid and cost-effective analysis of genetic data, revolutionizing fields like oncology, infectious diseases, and rare genetic disorders. As a result, the demand for NGS in clinical applications is skyrocketing, transforming the way we approach patient care and treatment.

Illumina: Illumina, a leading biotechnology company, develops and markets NGS systems, including the popular HiSeq and NovaSeq platforms. Their technology enables rapid and accurate genetic analysis, driving advancements in cancer research, rare disease diagnosis, and personalized medicine.Thermo Fisher Scientific: A global life sciences company, Thermo Fisher Scientific offers a range of NGS solutions, including the Ion Torrent and Applied Biosystems platforms. Their technology supports various clinical applications, such as noninvasive prenatal testing, cancer profiling, and infectious disease detection.

8.  Global 5G Chipset Market The market for 5G chipsets is growing rapidly! In 2022, it was valued at $26.1 billion, and it’s expected to increase to $30 billion by 2023 and then more than double to $72 billion by 2028, with an impressive annual growth rate of 19.1%. This surge is driven by the increasing demand for high-speed, low-latency connectivity in various industries, including smartphones, laptops, and emerging technologies like autonomous vehicles and smart cities. As 5G networks continue to expand globally, the need for advanced chipsets that enable fast and reliable data transfer is skyrocketing, making this market a hotbed of innovation and growth.

Qualcomm: Qualcomm, a leading semiconductor company, designs and manufactures 5G chipsets, including the popular Snapdragon series, which powers many smartphones and laptops. Their 5G chipsets enable fast data transfer, low latency, and improved connectivity.Mediatek: Mediatek, a Taiwanese semiconductor company, produces 5G chipsets for various applications, including smartphones, tablets, and smart home devices. Their 5G chipsets offer high-speed connectivity, power efficiency, and advanced features like AI processing.

Get ready for a revolution! The explosive growth in emerging technologies like viral vectors, inkjet printing, electric vehicle batteries, next-generation sequencing, and 5G chipsets is transforming industries and creating unprecedented opportunities. As these markets soar, businesses and investors can expect a thrilling ride of innovation, sustainability, and boundless potential. Buckle up and join the journey to a brighter, more connected, and more sustainable future!

For further information or to make a purchase, please get in touch with info@bccresearch.com.

About BCC Research

BCC Research provides objective, unbiased measurement, and assessment of market opportunities with detailed market research reports. Our experienced industry analysts’ goal is to help you make informed business decisions, free of noise and hype.

Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: info@bccresearch.com,
Phone: +1 781-489-7301

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/invest-smart-grow-fast-industries-with-up-to-20-annual-growth-302292013.html

Continue Reading

Technology

MiniTool ShadowMaker 5.0 Introduces Cloud Sync for Google Drive and OneDrive

Published

on

By

VANCOUVER, BC, Oct. 22, 2026 /PRNewswire/ — MiniTool® Software Limited has announced the release of MiniTool ShadowMaker 5.0, the latest version of its Windows backup and file sync software. The update introduces a new Cloud Sync feature for Google Drive and OneDrive, along with enhancements to the registration and purchase experience, interface refinements, and compatibility fixes.

New Features and Improvements in MiniTool ShadowMaker 5.0

1. Cloud Sync to Google Drive and OneDrive

MiniTool ShadowMaker 5.0 introduces Cloud Sync, allowing users to synchronize files and folders from a Windows computer to Google Drive or OneDrive. Users can choose the files and folders they want to sync and select their preferred cloud storage service as the destination.

The new feature supports one-way synchronization from a local Windows PC to cloud storage, providing an additional way to save copies of important files outside of your computer. Together with MiniTool ShadowMaker’s existing local file sync function, Cloud Sync expands the available destinations for file sync.

2. Streamlined License & Plan Management

The latest update introduces an enhanced register interface that remains easily accessible even after activation. Registered users can now effortlessly review their current plan, explore upgrade options, or update their license key anytime for a smoother user experience.

These refinements are intended to improve usability when users manage their software registration and licensing.

3. Interface Refinements and Compatibility Fixes

MiniTool ShadowMaker 5.0 includes interface improvements and fixes for certain display issues. One notable fix addresses a blurry display issue that could occur on some systems equipped with AMD GPUs.

These changes focus on resolving specific issues and improving the user experience on affected systems.

4. Additional Improvements

Beyond Cloud Sync and the changes outlined above, MiniTool ShadowMaker 5.0 includes additional interface and functionality refinements. Together, these updates further improve the software’s usability while expanding its file synchronization options.

With support for Google Drive and OneDrive, MiniTool ShadowMaker 5.0 provides Windows users with another approach to manage file copies across local and cloud storage. Users who want to synchronize files to cloud storage can download the Free Edition and explore the new capabilities.

About MiniTool ShadowMaker

MiniTool ShadowMaker is a Windows backup and file sync solution designed to help users protect their operating systems and important data. It supports backing up Windows systems, disks, partitions, files, and folders to local drives, external hard drives, shared folders, and other supported locations. Users can select specific items to back up according to their needs.

For users who need to migrate data to another drive, MiniTool ShadowMaker offers a disk cloning feature. The software also supports restoring backed-up data and creating bootable media for system recovery.

By combining backup, file synchronization, disk cloning, and restore capabilities, MiniTool ShadowMaker offers Windows users a set of tools for data protection and system recovery.

About MiniTool® Software Limited

MiniTool Software Limited is a professional software company that develops computer applications. It provides software for partition management, data recovery, data backup and sync, video editing, multimedia conversion, and screen recording for home and business users. The company is committed to developing innovative, reliable, and easy-to-use software that simplifies everyday digital tasks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/minitool-shadowmaker-5-0-introduces-cloud-sync-for-google-drive-and-onedrive-302916663.html

SOURCE MiniTool® Software Limited

Continue Reading

Technology

Rocket Companies to Announce Third Quarter 2026 Results on October 29, 2026

Published

on

By

DETROIT, Oct. 22, 2026 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or “the Company”), the Detroit-based homeownership platform, today announced that the Company will issue its third quarter 2026 earnings on October 29, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company’s results will be issued prior to the call.

A live webcast of the event will be available on the “Events & Presentations” section of the Company’s Investor Relations website at ir.rocketcompanies.com. A replay of the webcast will be available on the Investor Relations website following the event.

About Rocket Companies

Founded in 1985, Rocket Companies (NYSE: RKT) is a Detroit-based homeownership platform including mortgage, real estate and personal finance businesses: Rocket Mortgage, Redfin, Rocket Close, Rocket Money and Rocket Loans.

With insights from more than 160 million calls with clients each year, more than 30 petabytes of data and a mission to Help Everyone Home, Rocket Companies is well positioned to be the destination for AI-fueled homeownership.

For more information, please visit the Company’s Corporate website or Investor Relations website.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-companies-to-announce-third-quarter-2026-results-on-october-29-2026-302917496.html

SOURCE Rocket Companies, Inc.

Continue Reading

Technology

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

Published

on

By

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ — Lunai Bioworks Inc. (Nasdaq: LNAI) (the “Company”) announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2,500,000. The Company reported a stockholders’ deficit of $(9,024,946) in its Annual Report on Form 10-K for the fiscal year ended June 30, 2026, and does not meet the alternative market value of listed securities or net income standards. Because the Company is subject to a mandatory Hearings Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B), Nasdaq staff determined to delist the Company’s securities. Trading in the Company’s common stock on Nasdaq is expected to be suspended at the opening of business on October 30, 2026.

The Company will not request a hearing. Rather than contest the staff determination, the Company’s Board of Directors approved on October 22, 2026 the voluntary withdrawal of the Company’s common stock from listing on Nasdaq under Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended. The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.

The Company notified Nasdaq of its intention on October 22, 2026. The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026. The Company then intends to file a Form 15 to suspend its SEC reporting obligations, to the extent it is eligible to do so. The Company’s SEC reporting obligations will continue unless and until they are terminated or suspended in accordance with the SEC’s rules.

The Company does not intend to arrange for quotation of its common stock on any over-the-counter market and cannot assure that any trading market for its common stock will exist after trading on Nasdaq is suspended.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the expected suspension of trading, the expected timing of the Form 25 and Form 15 filings, and the expected timing of delisting and deregistration. Actual results may differ materially due to risks and uncertainties, including Nasdaq and SEC procedures and the Company’s financial condition. The Company undertakes no obligation to update these statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-announces-receipt-of-nasdaq-determination-and-intention-to-voluntarily-delist-and-deregister-302917510.html

SOURCE Lunai Bioworks Inc.

Continue Reading

Trending